Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH: Avelumab + Cetuximab + Radiotherapy vs Standard of Care in Locally Advanced Head and Neck Squamous Cell Carcinoma
2024-513964-24-00Phase 3Authorised
- Sponsor
- GORTEC
- Start
- Sep 2017
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised trial of avelumab, cetuximab and cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by GORTEC. Primary endpoint: Progression-Free Survival (PFS). Planned start Sep 2017; status: authorised.
02
Drugs
avelumabcetuximabcisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-513964-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513964-24-00.